Ronald Kotfila, MD
Gastroenterology · Flowood, MSNPI 1942298120
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.8%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Gastrogpo, LLC at 41.3% of the total. Reporting peaked in 2023 at $4,674 and has fallen 58.0% since, to $1,964 in 2025.
Across 172 payments — averaging $55.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gastrogpo, LLC$4K
- AstraZeneca$1K
- AbbVie$695
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$558
- Takeda Pharmaceuticals U.S.A., Inc.$466
- Pfizer$464
- plus $2K from 27 others
Across 5 payments — averaging $1915.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$10K
What the payments were for
- Consulting fees$1,16312%
- Speaking & faculty fees$2142%
- Travel & lodging$2,92631%
- Food & beverage$5,22555%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gastrogpo, LLC | 4 | $3,935 |
| AstraZeneca(2 entities) | 2 | $1,175 |
| AbbVie | 28 | $695 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 40 | $558 |
| Takeda Pharmaceuticals U.S.A., Inc. | 28 | $466 |
| Pfizer | 6 | $464 |
| Lucid Diagnostics Inc. | 9 | $402 |
| Mindray DS USA, Inc. | 1 | $230 |
| Fujifilm Healthcare Americas Corporation | 1 | $154 |
| Phathom Pharmaceuticals, Inc. | 9 | $152 |
| Boston Scientific | 4 | $147 |
| Ambu Inc. | 1 | $145 |
| Enterra Medical, Inc. | 2 | $145 |
| Medtronic | 1 | $117 |
| Anx Robotica Corp | 1 | $101 |
| Intercept Pharmaceuticals, Inc. | 6 | $100 |
| Ironwood Pharmaceuticals, Inc | 4 | $59 |
| Johnson & Johnson | 3 | $54 |
| Bristol Myers Squibb | 2 | $52 |
| Nestle Healthcare Nutrition Inc. | 3 | $51 |
| Braintree Laboratories, Inc. | 2 | $48 |
| Pentax Of America, Inc. | 2 | $35 |
| Ardelyx, Inc. | 2 | $33 |
| Echosens North America, Inc. | 1 | $31 |
| Merck | 2 | $30 |
| Sanofi | 1 | $28 |
| Redhill Biopharma Inc. | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Ferring Pharmaceuticals Inc. | 1 | $17 |
| Novo Nordisk | 1 | $17 |
| Aimmune Therapeutics, Inc. | 1 | $14 |
| Evoke Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,528 in reported general payments places this provider in the 75th percentile of 127 gastroenterology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 78 | $63,399 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 37 | $5,983 |
| Famotidine | 292 | $4,582 |
| Dexlansoprazole DrDexlansoprazole | 18 | $4,336 |
| NexiumEsomeprazole Magnesium | 13 | $3,901 |
| Omeprazole | 282 | $2,967 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 16 | $2,257 |
| Lubiprostone | 14 | $2,181 |
| Esomeprazole Magnesium | 26 | $2,052 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 65 | $1,706 |
| Dicyclomine Hcl | 114 | $1,550 |
| Pantoprazole Sodium | 146 | $1,477 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 86 | $1,381 |
| Budesonide DrBudesonide | 20 | $1,325 |
| Ondansetron OdtOndansetron | 57 | $1,265 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $695 | $63,39978 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $17 | $5,98337 claims |
| AstraZenecaNexium | $1,175 | $3,90113 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu | $558 | $2,25716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 127 gastroenterology providers in Mississippi.
Other gastroenterology in Flowood
- Reed HoganFlowood$216K
- Vonda ReevesFlowood$39K
- Reed HoganFlowood$35K
- Jane Claire WilliamsFlowood$16K
- Stewart BoydFlowood$4K
- Wassem JuakiemBiloxi$519K
- John PhillipsTupelo$150K
- Brian BorgJackson$68K
- Pegah Hosseini-CarrollJackson$62K
- Shou Jiang TangJackson$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.